<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371890</url>
  </required_header>
  <id_info>
    <org_study_id>092018-018</org_study_id>
    <nct_id>NCT01371890</nct_id>
  </id_info>
  <brief_title>Mechanisms and Treatment of Intradialytic Hypertension - Sodium</brief_title>
  <acronym>MATCH-Sodium</acronym>
  <official_title>Mechanisms and Treatment of Intradialytic Hypertension - Sodium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the role of dialysate exposure and fluid removal&#xD;
      during hemodialysis in the pathophysiology of intradialytic hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim #1 To determine in a crossover study of 15 maintenance hemodialysis patients&#xD;
      with intradialytic hypertension whether standard dialysis with ultrafiltration (dialysate Na&#xD;
      of 140), dialysis without ultrafiltration (dialysate Na of 140), or ultrafiltration alone (no&#xD;
      dialysate) is associated with the an increase in systolic blood pressure during hemodialysis&#xD;
&#xD;
      Specific Aim #2 To determine in a crossover study of 15 maintenance hemodialysis with&#xD;
      intradialytic hypertension whether standard dialysis with ultrafiltration, dialysis without&#xD;
      ultrafiltration, or ultrafiltration alone is associated with change in either endothelin-1 or&#xD;
      nitric oxide during hemodialysis&#xD;
&#xD;
      SUBSTUDY AIMS&#xD;
&#xD;
      Specific Aim #1 To determine in a randomized 3-week, 2 period crossover study of 15&#xD;
      maintenance hemodialysis patients with intradialytic hypertension whether high vs low&#xD;
      dialysate-to-serum Na gradients impairs release of NO, increases ET-1 or causes an acute&#xD;
      intradialytic increase in systolic BP,.&#xD;
&#xD;
      Specific Aim #2 TO determine in a randomized 16-week, 2-period crossover study of 30&#xD;
      hemodialysis patients with intradialytic hypertension the effects of 8 weeks of high&#xD;
      dialysate-to-plasma Na gradients to 8-weeks of low Na gradients on EC function (FMD and ADMA)&#xD;
      and 44 hour ambulatory BP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>crossover studies followup 3-16 weeks</time_frame>
    <description>Differences in blood pressure during hemodialysis between treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell function</measure>
    <time_frame>crossover studies with followup of 3-16 weeks</time_frame>
    <description>Differences in nitric oxide and endothelin-1 across treatments Differences in FMD and ADMA between treatments</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">18</enrollment>
  <condition>Hemodialysis</condition>
  <condition>End-stage Renal Disease</condition>
  <condition>Hypertension</condition>
  <condition>Intradialytic Hypertension</condition>
  <arm_group>
    <arm_group_label>Intradialytic hypertension</arm_group_label>
    <description>Patients with systolic blood pressure increases &gt; 10 mmHg during 4/6 hemodialysis sessions</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples stored for nitric oxide and endothelin-1 measurements&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Our study population will include up to 45 ESRD patients whose BP increases during&#xD;
        hemodialysis. Patients who dialyze at any of the 3 UT Southwestern-affiliated dialysis&#xD;
        units will be screened for possible enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  on hemodialysis &gt; 30 days&#xD;
&#xD;
          -  male and female participants, aged 18 to 85 years old, of all races and ethnic origin&#xD;
&#xD;
          -  ability to provide informed consent&#xD;
&#xD;
          -  Primary nephrologist deems patient is at target dry weight&#xD;
&#xD;
          -  KDOQI defined hypertension (predialysis SBP &gt;140 or postdialysis SBP&gt;130) AND&#xD;
&#xD;
          -  pre to post hemodialysis SBP increase (&gt;10 mmHg) during 4/6 last HD session&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active cancer or active wounds&#xD;
&#xD;
          -  Patient currently on antibiotics or on IV antibiotics within the last month&#xD;
&#xD;
          -  BP unable to be measured by routine mechanisms in the upper extremity&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Larger interdialytic weight gain (&gt;5 kg/treatment on average)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jula K Inrig, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>end-stage renal disease</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

